You need to enable JavaScript to run this app.
Recon: BMS to buy Mirati for up to $5.8 billion; Alnylam drops expanded indication for heart disease drug after FDA rejection
Recon
Jason Scott
Global
ReconJason Scott
GlobalReconJason ScottGlobal